Voting Rights and Shares Capital of the Company

Rhea-AI Summary

NANOBIOTIX (NASDAQ: NBTX) disclosed its voting rights and share capital as of November 30, 2025. The company reported 48,401,118 shares outstanding, 50,101,699 theoretical (gross) voting rights and 50,079,581 exercisable (net) voting rights.

Disclosure follows French legal requirements (articles L.233-8 II and AMF Article 223-16). NANOBIOTIX is listed on Euronext Paris and Nasdaq Global Select Market and holds over 25 patent families across three nanotechnology platforms with operations in France and the United States.

Key Figures

Shares outstanding 48,401,118 Number of shares outstanding as of November 30, 2025

Theoretical voting rights 50,101,699 Total theoretical (gross) voting rights as of November 30, 2025

Exercisable voting rights 50,079,581 Total exercisable (net) voting rights as of November 30, 2025

Patent families more than 25 Patent families across three nanotechnology platforms

Nanotechnology platforms 3 Platforms in oncology, bioavailability/biodistribution, CNS disorders

Market Reality Check

$22.88 Last Close

Volume Volume 15,692 vs 20-day average 44,987 ahead of this disclosure filing. low

Technical Price 22.32 is trading above 200-day MA at 10.11 before this notice.

Peers on Argus

Peers show mixed moves: REPL -2.73%, OPT -2.01%, ERAS +3.53%, while BCYC 0% and ARCT -0.42%, suggesting no clear sector-wide driver for this administrative voting-rights update.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 15	Index inclusion	Positive	-1.6%	Announcement of entry into CAC Mid 60 and SBF 120 indices.
Nov 24	Operations & financing	Positive	+5.1%	Q3 update with royalty financing and extended cash visibility.
Nov 14	Capital structure update	Neutral	+2.6%	Disclosure of shares outstanding and voting rights per AMF rules.
Nov 13	Platform advancement	Positive	+2.6%	Curadigm Nanoprimer IP expansion and new preclinical data.
Nov 11	Conference participation	Neutral	+3.1%	Jefferies London Healthcare Conference fireside chat announcement.

Pattern Detected

Recent corporate and operational updates, including index inclusion and platform progress, generally saw price moves aligning with the positive or neutral tone, with one divergence on index inclusion news.

Recent Company History

Over the past months, Nanobiotix reported several milestones. On November 24, 2025, it highlighted a $50 million royalty financing, expected $21 million contingent payment, €20.4 million cash, and projected cash visibility into early 2028. Earlier in November, it advanced the Curadigm Nanoprimer platform and announced participation in a major healthcare conference. Index inclusion in the CAC Mid 60 and SBF 120 was announced on December 15, 2025. Today’s voting rights disclosure follows a similar share-capital notice from October 31, 2025.

Market Pulse Summary

This announcement provides an updated snapshot of Nanobiotix’s capital structure as of November 30, 2025, detailing 48,401,118 shares outstanding and both theoretical and exercisable voting rights, in line with French AMF disclosure rules. It follows a prior voting-rights notice from October 31, 2025, helping investors track changes in share count and voting power. Investors may also monitor upcoming clinical, financial, and index-related developments alongside these routine governance updates.

Key Terms

isin code financial

"Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205"

An ISIN code is a unique identifier for a specific financial asset, like a stock or bond, similar to a product's barcode. It helps investors, traders, and banks quickly and accurately find and track that asset across different markets worldwide. This makes buying, selling, and managing investments more organized and reliable.

nanotechnology technical

"more than 25 patent families associated with three (3) nanotechnology platforms"

Nanotechnology is the design and control of materials and devices at the scale of atoms and molecules — about one-billionth of a meter — allowing scientists to create properties and functions not possible at larger sizes. For investors, it matters because these tiny changes can lead to big improvements in drugs, electronics, materials and manufacturing efficiency, opening new markets and competitive advantages while also bringing technical, cost and regulatory risks.

oncology medical

"three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability"

Oncology is the branch of medicine focused on understanding, diagnosing, and treating cancer, including the development and testing of drugs, therapies, and screening methods. It matters to investors because advances, trial results, regulatory approvals, or setbacks in cancer research can dramatically change the value of companies and the size of potential markets—think of oncology news as weather reports that help investors steer financial decisions in a high-stakes field.

bioavailability medical

"applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders"

Bioavailability is the measure of how much and how quickly a substance, such as a medication or nutrient, enters the bloodstream and becomes available for use by the body. For investors, it matters because it influences how effectively a product works and how quickly results are seen, which can impact a company's success and the potential value of related investments. Think of it like how much of a medicine actually reaches your bloodstream after taking it—that determines how well it can do its job.

biodistribution medical

"applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders"

Biodistribution is the map of where a drug, vaccine, or diagnostic agent travels and accumulates inside the body after administration. Investors care because where a product ends up affects how well it works, what side effects it may cause, and whether regulators will approve it—similar to tracking dye in a plumbing system to find leaks or blockages; unexpected destinations can raise safety, cost, and market-adoption risks.

central nervous system medical

"applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system."

The central nervous system (CNS) is the body's main control center, made up of the brain and spinal cord, that processes information and directs movement, sensation and basic functions like breathing. For investors, CNS-related products and research matter because they face long development times, strict safety testing and regulatory hurdles; success or failure can dramatically affect a company’s costs, timelines and potential market value.

AI-generated analysis. Not financial advice.

In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)

PARIS, Dec. 17, 2025 (GLOBE NEWSWIRE) --
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com

Date	Number of Shares Outstanding	Total number of voting rights
		Total voting rights, theoretical1	Total voting rights, exercisable2
November 30, 2025	48,401,118	50,101,699	50,079,581

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.

Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.

__________________________________

¹ The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

² The total number of exercisable at a shareholders’ meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed.

Contacts

Nanobiotix
Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com	Investor Relations Department Joanne Choi VP, Investor Relations (US) +1 (713) 609-3150 Ricky Bhajun Director, Investor Relations (EU) investors@nanobiotix.com
Media Relations
France – HARDY Caroline Hardy +33 06 70 33 49 50 carolinehardy@outlook.fr	Global – uncapped Becky Lauer +1 (646) 286-0057 uncappednanobiotix@uncappedcommunications.com

Attachment

• 2025-12-17 -- NBTX -- Voting Rights & Shares Capital -- FINAL

FAQ

What voting rights figures did NANOBIOTIX (NBTX) report on December 17, 2025?

As of November 30, 2025 NANOBIOTIX reported 48,401,118 shares outstanding, 50,101,699 theoretical voting rights and 50,079,581 exercisable voting rights.

Why did NANOBIOTIX (NBTX) publish voting rights and share capital information on Dec 17, 2025?

The disclosure was made to comply with French rules (Article L.233-8 II and AMF Article 223-16) that require public reporting of voting rights and shares.

How are NANOBIOTIX (NBTX) theoretical and exercisable voting rights defined?

Theoretical (gross) voting rights include all shares with attached voting rights; exercisable (net) voting rights exclude shares with suspended voting rights such as treasury stock.

Where is NANOBIOTIX (NBTX) listed and what is its ISIN as of Dec 17, 2025?

NANOBIOTIX is listed on Euronext Paris and the Nasdaq Global Select Market with ISIN FR0011341205 and Nasdaq symbol NBTX.

Who can investors contact for more information about NANOBIOTIX (NBTX) shareholder data?

Investor relations contacts include Joanne Choi (US VP Investor Relations) and Ricky Bhajun (EU Director Investor Relations) via the company investor relations email.